The Drugs Controller General of India (DCGI) has granted its approval to Natco Pharma for launching a generic version of US biotechnology firm Gilead Sciences' Hepatitis C drug in India. Under the deal, Natco can expand the drug's access to 91 countries. The treatment, under the brand name 'Hepcinat LP', would cost â‚¹25,000 for a bottle having 28 tablets.